A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris.

Trial Profile

A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2014

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Creabilis SA
  • Most Recent Events

    • 21 Mar 2014 Results will be presented at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) according to a Creabilis SA media release.
    • 10 May 2013 Top-line results reported in a Creabilis media release.
    • 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top